EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advancing glioblastoma therapy: Learning from the past and innovations for the future

Mandeep Rana, Ke-Chi Liou, Amandeep Thakur, Kunal Nepali, Jing-Ping Liou

Cancer Letters · 2025-05 · 617 · 217601

DOI: 10.1016/j.canlet.2025.217601 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-05. Verfasst von Mandeep Rana und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 286 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Marred by a median survival of only around 12-15 months coupled with poor prognosis and effective therapeutic deprived drug armory, treatment/management of glioblastoma has proved to be a daunting task. Surgical resection, flanked by radiotherapy and chemotherapy with temozolomide, stands as the standard of care; however, this trimodal therapy often manifests limited efficacy due to the heterogeneous and highly infiltrative nature of GBM cells. In addition, the existence of the blood-brain barrier, tumor microenvironment, and the immunosuppressive nature of GBM, along with the encountered resistance of GBM cells towards conventional therapy, also hinders the therapeutic applications of chemotherapeutics in GBM. This review presents key insights into the molecular pathology of GBM, including genetic mutations, signaling pathways, and tumor microenvironment characteristics. Recent innovations such as immunotherapy, oncolytic viral therapies, vaccines, nanotechnology, electric field, and cancer neuroscience, as well as their clinical progress, have been covered. In addition, this compilation also encompasses a discussion on the role of personalized medicine in tailoring treatments based on individual tumor profiles, an approach that is gradually shifting the paradigm in GBM management. Endowed with the learnings imbibed from past failures coupled with the zeal to embrace novel/multidisciplinary approaches, researchers appear to be on the right track to pinpoint more effective and durable solutions in the context of GBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTumor MicroenvironmentImmunotherapyPrecision MedicineAnimals

Stichwörter der Autor:innen

GlioblastomaImmunotherapyMetabolismNeuronsTumor microenvironment

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan.
  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, 110, Taiwan; Ph.D. Program in Drug Discovery and Develo…

Förderung

  • National Science and Technology Council

Zitieren

APA

Rana, M., Liou, K. C., Thakur, A., Nepali, K., & Liou, J. P. (2025). Advancing glioblastoma therapy: Learning from the past and innovations for the future. Cancer Letters, 617, 217601. https://doi.org/10.1016/j.canlet.2025.217601

Vancouver

Rana M, Liou KC, Thakur A, Nepali K, Liou JP. Advancing glioblastoma therapy: Learning from the past and innovations for the future. Cancer Letters. 2025;617:217601. doi:10.1016/j.canlet.2025.217601

BibTeX
@article{Rana2025,
  author = {Rana, Mandeep and Liou, Ke-Chi and Thakur, Amandeep and Nepali, Kunal and Liou, Jing-Ping},
  title = {Advancing glioblastoma therapy: Learning from the past and innovations for the future},
  journal = {Cancer Letters},
  year = {2025},
  volume = {617},
  pages = {217601},
  doi = {10.1016/j.canlet.2025.217601}
}
Kostenlos starten →